How to Choose a Growth Hormone Peptide (2026)

Four peptides, one decision: how to choose a growth hormone peptide by your goal, the actual evidence, and your personal risk profile — not by which one is “strongest.”

Abstract: This guide gives you a research-framed way to choose a growth hormone peptide among sermorelin, ipamorelin, CJC-1295 and tesamorelin, built on the underlying GH-axis physiology and the human evidence for each. The single most useful idea: the goal is to augment your natural GH pulses, not to override them — which is why the “strongest” option is rarely the right one.

Most comparisons rank these peptides by potency and then point you at a stack. That misses the question that actually matters. Knowing how to choose a growth hormone peptide is less about which molecule raises GH the most and more about how it raises it, what the human data actually show, and whether your own labs and risk profile point toward more elevation or less. This guide walks through the physiology, grades the evidence honestly (one popular option has zero human studies), and ends with a decision matrix you can take to a clinician.

This is educational, research-use-only content — not medical advice or a dosing directive. See the disclaimer at the end.

The one idea that should drive your choice

Growth hormone is released in pulses, not a steady stream — roughly 93% of daily GH comes in bursts every 2–3 hours, with the largest pulse arriving shortly after you fall asleep. Here is the fact that reframes the whole category: aging lowers the amplitude of those pulses, not their frequency and not your baseline GH. GH output falls about 1% per year after age 30 (a process called somatopause), and it does so mainly by flattening the peaks.

That single detail tells you what a good GH peptide should do — restore pulse height, then let GH fall back to a low trough — and what a bad one does: prop up your baseline GH around the clock so you never return to the trough. Those low troughs matter. They’re when AMPK and sirtuin “repair and clean-up” pathways switch on; living in a permanently GH-elevated state keeps you in mTOR/IGF-1 growth signaling instead. So the right mental model isn’t “more GH = better.” It’s augment the physiology, don’t override it. Keep that lens and the four options sort themselves out quickly.

It’s also worth being honest that raising GH/IGF-1 is not a free anti-aging win. Higher IGF-1 carries real trade-offs — insulin resistance and a well-documented association with cancer progression (each +38 ng/mL of IGF-1 is associated with roughly an 8–18% higher risk for several common cancers; GH doesn’t cause cancer but can feed an existing one), and a likely U-shaped relationship between IGF-1 and mortality where both too-low and too-high are unfavorable [Nass 2008]. That’s exactly why the decision should be personalized rather than maximized. For a broader look at the GH-versus-secretagogue question, see our overview of HGH peptide therapy benefits and risks.

The two classes you’re actually choosing between

Every peptide here belongs to one of two families, and they’re designed to be used together, not against each other.

GHRH analogs mimic your natural growth-hormone-releasing hormone and tell the pituitary to release a pulse. Sermorelin, CJC-1295 and tesamorelin are all GHRH analogs — they differ mainly in stability, potency and how much human data sits behind them. This is the “base” of any protocol.

GHRPs (growth hormone-releasing peptides) work through a different door — the ghrelin/GHSR-1A receptor — and both add to the GHRH pulse and release the somatostatin “brake.” Ipamorelin is a GHRP. It’s the optional “add-on,” used for synergy rather than raw potency.

So the practical decision is really two smaller ones: which GHRH base, and whether to add ipamorelin. The reason you don’t just take a GHRP alone is mechanistic and important: GHRP monotherapy fails over time because the GHSR receptor rapidly desensitizes and chronic GHRP raises somatostatin, so IGF-1 stops rising. A GHRH base desensitizes far less and actually upregulates the GHSR receptors — which is why the combination produces a documented ~66% synergistic GH increase over either alone [Ionescu 2019]. This is the real basis for the popular CJC-1295 + ipamorelin “gold standard” stack.

The four peptides, by evidence

Here’s where honest grading matters more than marketing. The options are not equally proven.

Sermorelin — the gentle, well-tolerated starter

Sermorelin is the original GHRH analog (the first 29 amino acids of GHRH, unmodified; half-life ~10–20 minutes). Across roughly 100 adults in small studies it raised IGF-1 by about +50% with body-composition gains — and notably, it tends to improve insulin sensitivity rather than worsen it, which sets it apart from the more potent options [Sigalos 2018]. It’s also the cheapest of the group, roughly 3–4× less than tesamorelin.

It’s framed as the physiologic “starter” for good reason: it nudges your natural pulsatility up rather than forcing it. If you respond well, great; if you’ve worked up to a moderate dose and see nothing, the move is to switch to a more potent GHRH rather than keep climbing. See our beginner-oriented look at gentle GH secretagogues for where this fits.

Tesamorelin — the most-studied, best for visceral fat

Tesamorelin is GHRH stabilized with a trans-hexenoic acid group, and it’s the only peptide here that’s FDA-approved (for HIV-associated lipodystrophy), with 1,000+ patients in its trial record. The data are the strongest in the category: roughly +80% IGF-1, an 11–18% reduction in visceral fat, lower triglycerides, higher HDL and reduced inflammation [Falutz 2007; Stanley 2014]. If your primary goal is visceral (belly) fat, this is the evidence-backed pick — see tesamorelin for visceral fat.

The honest caveat is metabolic: tesamorelin can transiently worsen insulin resistance early (fasting glucose rose ~9 mg/dL at two weeks), an effect that normalized by ~6 months if visceral fat was actually lost. Among people who lost less than 8% of their visceral fat, glucose and A1C stayed elevated, and about 5% developed diabetes versus 1% on placebo [Stanley 2014]. Roughly half of patients formed antibodies, but efficacy was unaffected and they waned over time. It’s also the most expensive option.

CJC-1295 (without DAC) — mechanistically attractive, clinically unproven

This is the one that requires the most care, partly because of a naming trap. In the scientific literature, “CJC-1295” means the with-DAC version — a long-acting form (half-life 5.8–8.1 days) that’s a fundamentally different peptide from what’s usually sold for daily use. The without-DAC form (also called modified GRF 1-29) carries four amino-acid changes that give it roughly 4× the potency of sermorelin in animal models, with a short half-life (~20–50 min) that keeps it pulsatile.

The catch: the without-DAC form has no human studies — its effects are inferred, not demonstrated. Mechanistically it’s appealing (potent but physiologic, and cost-effective), which is why it’s popular, but the evidence tier is genuinely low. If you choose it, do so understanding you’re betting on mechanism, not outcomes. See our CJC-1295 (no DAC) overview.

Ipamorelin — the only selective GHRP, used for synergy

Ipamorelin is the standout among GHRPs for one reason: selectivity. It raises GH about as well as older GHRPs but, unlike them, doesn’t meaningfully stimulate cortisol, ACTH or prolactin even at high doses [Raun 1998]. That clean profile is why it’s the default add-on. The key framing: you use ipamorelin with a GHRH base for synergy, not alone — on its own it desensitizes and stops working. More detail in our ipamorelin selective secretagogue guide.

The DAC problem — and why “strongest” can be wrong

It’s worth dwelling on why CJC-1295 with DAC sits off to the side for anyone prioritizing long-term health. The DAC modification binds the peptide to albumin and extends its half-life to nearly a week. That sounds convenient, but it raises basal/trough GH about 7.5× while leaving pulse amplitude essentially unchanged. Reread the opening idea: aging is lost amplitude, not low baseline. So the with-DAC version delivers precisely the wrong shape of GH exposure — chronic elevation that prevents the low troughs where repair pathways activate. The same critique applies to MK-677/ibutamoren (an oral non-peptide secretagogue), which raises trough GH ~3.5× and is associated with insulin resistance.

There’s also a safety footnote: a with-DAC phase-2 trial was terminated and never published after a participant death (deemed unrelated, cardiac), which is reason enough for extra caution. The short-acting GHRHs do the opposite of DAC — they raise pulse amplitude up to ~2.5× and return to baseline, which is the physiologic pattern you want. This is the clearest example of why “strongest” or “longest-lasting” is the wrong selection criterion.

At-a-glance comparison

Peptide	Class	Human evidence	IGF-1 effect	Best for	Watch-outs
Sermorelin	GHRH analog	~100 adults	~+50%	Gentle start, GH-axis preservation, insulin-sensitive users	Mild/slow; may need to step up
Tesamorelin	GHRH analog	1,000+ (FDA-approved)	~+80%	Visceral fat, dyslipidemia	Early insulin resistance; most expensive
CJC-1295 (no DAC)	GHRH analog	None (inferred)	Presumed high	Cost-effective potency if you accept unproven status	No outcome data
Ipamorelin	GHRP (add-on)	Animal + small human	Modest alone	Synergy with a GHRH; clean side-effect profile	Fails as monotherapy

For the full head-to-head ranking with potency and dosing detail, see our companion growth hormone peptides compared. For the fat-loss-specific question, tesamorelin vs ipamorelin drills into that match-up.

How to choose a growth hormone peptide: the decision framework

Put the molecules aside for a moment and start with two questions: what’s your goal, and what do your labs and risk profile say about how hard to push?

Pick your GHRH base by goal and starting point. If you’re new, over ~60, female, or simply want the gentlest physiologic option, start with sermorelin — the adverse-effect risk is lowest and you titrate up only if needed. If your primary target is visceral fat, high triglycerides or low HDL, the evidence points to tesamorelin. If you want potency at lower cost and you genuinely accept that human outcome data don’t exist, CJC-1295 without DAC is the mechanistically-reasonable-but-unproven middle. For health and longevity priorities, CJC-1295 with DAC is off the table.

Add ipamorelin only if you want synergy. A GHRH base alone is a complete protocol. If you add a GHRP, make it the selective one — ipamorelin, or a convenience combination like ipamorelin + tesamorelin — and understand you’re doing it for the ~66% synergy, not because more is automatically better.

Let your risk profile set the dial. Lean toward more elevation if you have low IGF-1, high visceral fat, an unfavorable lipid panel and low muscle mass. Lean toward less, or avoid entirely, if you have high IGF-1 already, insulin resistance or diabetes, a tendency to fluid retention, or — this one is a full stop — an active or genetic predisposition to cancer. The IGF-1/cancer relationship is real and worth understanding before you start; our piece on GLP-1 and cancer risk covers the broader growth-signaling-and-cancer logic that applies here too.

Whatever you choose, monitor. Track IGF-1 (keep it in range, not maxed), fasting glucose and A1C, lipids, and run cancer screening appropriate to your age before starting. Review the peptide side effects and safety guide before any protocol.

FAQ

Which growth hormone peptide is best? There’s no universal “best” — it depends on goal and risk profile. For the strongest human evidence and visceral fat, tesamorelin; for a gentle, insulin-sensitive start, sermorelin; for clean synergy as an add-on, ipamorelin. CJC-1295 without DAC is potent in theory but has no human outcome data.

Is sermorelin or ipamorelin better? They’re not really competitors — sermorelin is a GHRH base and ipamorelin is a GHRP add-on, and they’re designed to be used together. If you must pick one to start alone, a GHRH like sermorelin is the better standalone choice, because ipamorelin loses effect when used as monotherapy.

What’s the difference between CJC-1295 with and without DAC? The DAC version binds albumin and lasts ~5.8–8.1 days, raising baseline GH ~7.5× — non-physiologic and off the table for longevity-minded use. The without-DAC version is short-acting and pulsatile (~20–50 min), which preserves the natural GH rhythm, but it has no human studies.

Do these peptides build muscle like HGH? They raise your own GH and IGF-1 rather than replacing them, so effects are more modest and physiologic than injected HGH — the trade being a better safety and cost profile. They augment recovery, sleep and body composition more than they drive raw hypertrophy.

Why combine a GHRH with a GHRP at all? Because the two mechanisms synergize: a GHRH base raises the pulse and upregulates the GHSR receptor, while a GHRP adds to the pulse and lifts the somatostatin brake. Together they produce roughly a 66% greater GH increase than either alone, and the GHRH base prevents the receptor desensitization that makes GHRP-only protocols fade.

References

1. Raun, K. et al. (1998). Ipamorelin, the First Selective Growth Hormone Secretagogue. European Journal of Endocrinology. doi:10.1530/eje.0.1390552
2. Falutz, J. et al. (2007). Metabolic Effects of Tesamorelin in HIV-Associated Lipodystrophy. New England Journal of Medicine. PMID 18057338 · doi:10.1056/NEJMoa072375
3. Stanley, T.L. et al. (2014). Effects of Tesamorelin on Visceral Fat and Liver Fat. JAMA. PMID 25038357 · doi:10.1001/jama.2014.8334
4. Sigalos, J.T. & Pastuszak, A.W. (2018). The Safety and Efficacy of Growth Hormone Secretagogues. Sexual Medicine Reviews. PMID 28400207 · doi:10.1016/j.sxmr.2017.02.004
5. Teichman, S.L. et al. (2006). Prolonged Stimulation of GH and IGF-I by CJC-1295. Journal of Clinical Endocrinology & Metabolism. doi:10.1210/jc.2005-1536
6. Nass, R. et al. (2008). GH Axis and Aging. Best Practice & Research Clinical Endocrinology & Metabolism.

---

Research and educational use only. This article describes what has been used or reported in research and is not medical advice, a treatment recommendation, or a dosing directive. Growth hormone peptides are not approved for anti-aging or performance use; tesamorelin is approved only for HIV-associated lipodystrophy. Raising GH/IGF-1 carries real risks (insulin resistance, cancer progression). Consult a qualified clinician and do appropriate screening before considering any protocol.